Spots Global Cancer Trial Database for trastuzumab [herceptin]
Every month we try and update this database with for trastuzumab [herceptin] cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | NCT02402712 | Breast Cancer | Docetaxel pertuzumab [Per... trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer | NCT00811135 | Breast Cancer | bevacizumab [Av... capecitabine [X... trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer | NCT00811135 | Breast Cancer | bevacizumab [Av... capecitabine [X... trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin | NCT01152606 | Breast Cancer | trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer | NCT00964704 | Breast Cancer | bevacizumab [Av... capecitabine [X... docetaxel trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer | NCT00964704 | Breast Cancer | bevacizumab [Av... capecitabine [X... docetaxel trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | NCT01120184 | Breast Cancer | docetaxel paclitaxel pertuzumab pertuzumab-plac... trastuzumab [He... trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer | NCT01260194 | Gastric Cancer | trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer | NCT00885755 | Breast Cancer | Standard taxane... capecitabine [X... trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer. | NCT00717405 | Breast Cancer | Standard chemot... bevacizumab [Av... trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer | NCT00964704 | Breast Cancer | bevacizumab [Av... capecitabine [X... docetaxel trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | NCT02402712 | Breast Cancer | Docetaxel pertuzumab [Per... trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | NCT00811993 | Neoplasms | RG1507 RO1507 bevacizumab [Av... capecitabine [X... carboplatin cetuximab docetaxel erlotinib [Tarc... etoposide gemcitabine irinotecan mFOLFOX6 paclitaxel pemetrexel sorafenib temozolomide trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer. | NCT00717405 | Breast Cancer | Standard chemot... bevacizumab [Av... trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer | NCT00964704 | Breast Cancer | bevacizumab [Av... capecitabine [X... docetaxel trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy. | NCT01290718 | Breast Cancer | capecitabine [X... trastuzumab [He... | 18 Years - 65 Years | Hoffmann-La Roche | |
| A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer | NCT01130337 | Gastric Cancer | Capecitabine [X... Oxaliplatin Trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer | NCT00885755 | Breast Cancer | Standard taxane... capecitabine [X... trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | NCT01120184 | Breast Cancer | docetaxel paclitaxel pertuzumab pertuzumab-plac... trastuzumab [He... trastuzumab emt... | 18 Years - | Hoffmann-La Roche | |
| A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer | NCT01130337 | Gastric Cancer | Capecitabine [X... Oxaliplatin Trastuzumab [He... | 18 Years - | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
